Search research articles
Contact Us
Filters
Showing results (21-30 of 635) with videos related to
Page
of 64
Sort By:
Annals of Surgical Oncology
|
July 11, 2021
ASO Author Reflections: Long-Term Survivors after Upfront Resection for Pancreatic Cancer: Do They Really Exist?
Giulio Belfiori, Stefano Crippa, Massimo Falconi
Hepatobiliary Surgery and Nutrition
|
April 26, 2021
Screening for pancreatic cancer-a compelling challenge
Gabriele Capurso, Salvatore Paiella, Massimo Falconi
Journal of Hepato-Biliary-Pancreatic Sciences
|
October 30, 2009
Parenchyma-sparing resections for pancreatic neoplasms
Stefano Crippa, Letizia Boninsegna, Stefano Partelli, et al.
Recenti Progressi in Medicina
|
July 1, 2016
[Pancreatic cancer]
Massimo Falconi, Domenico Tamburrino, Elena Buzzetti, et al.
Annals of Surgery
|
December 6, 2019
Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeon Is Just as Good for the Patient?
Gianpaolo Balzano, Nicolò Pecorelli, Massimo Falconi, et al.
Annals of Surgical Oncology
|
June 7, 2022
ASO Author Reflections: The Impact of CT-assessed Liver Steatosis on Postoperative Complications after Pancreaticoduodenectomy for Cancer
Nicolò Pecorelli, Giovanni Guarneri, Diego Palumbo, et al.
Surgery
|
December 25, 2012
The natural history of a branch-duct intraductal papillary mucinous neoplasm of the pancreas
Stefano Crippa, Stefano Partelli, Domenico Tamburrino, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2018
Somatostatin analogs: is one better than other?
Rossana Berardi, Stefano Partelli, Stefano Cascinu, et al.
Annals of Surgical Oncology
|
September 15, 2020
ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma
Domenico Tamburrino, Giovanni Guarneri, Gabriele Capurso, et al.
Expert Opinion on Pharmacotherapy
|
September 29, 2020
Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey
Massimo Falconi, Nicola Fazio, Diego Ferone, et al.
Page
of 64
Search research articles
Search
Showing results (21-30 of 635) with videos related to
Sort By:
Page
of 64
Annals of Surgical Oncology
|
July 11, 2021
ASO Author Reflections: Long-Term Survivors after Upfront Resection for Pancreatic Cancer: Do They Really Exist?
Giulio Belfiori, Stefano Crippa, Massimo Falconi
Hepatobiliary Surgery and Nutrition
|
April 26, 2021
Screening for pancreatic cancer-a compelling challenge
Gabriele Capurso, Salvatore Paiella, Massimo Falconi
Journal of Hepato-Biliary-Pancreatic Sciences
|
October 30, 2009
Parenchyma-sparing resections for pancreatic neoplasms
Stefano Crippa, Letizia Boninsegna, Stefano Partelli, et al.
Recenti Progressi in Medicina
|
July 1, 2016
[Pancreatic cancer]
Massimo Falconi, Domenico Tamburrino, Elena Buzzetti, et al.
Annals of Surgery
|
December 6, 2019
Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeon Is Just as Good for the Patient?
Gianpaolo Balzano, Nicolò Pecorelli, Massimo Falconi, et al.
Annals of Surgical Oncology
|
June 7, 2022
ASO Author Reflections: The Impact of CT-assessed Liver Steatosis on Postoperative Complications after Pancreaticoduodenectomy for Cancer
Nicolò Pecorelli, Giovanni Guarneri, Diego Palumbo, et al.
Surgery
|
December 25, 2012
The natural history of a branch-duct intraductal papillary mucinous neoplasm of the pancreas
Stefano Crippa, Stefano Partelli, Domenico Tamburrino, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2018
Somatostatin analogs: is one better than other?
Rossana Berardi, Stefano Partelli, Stefano Cascinu, et al.
Annals of Surgical Oncology
|
September 15, 2020
ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma
Domenico Tamburrino, Giovanni Guarneri, Gabriele Capurso, et al.
Expert Opinion on Pharmacotherapy
|
September 29, 2020
Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey
Massimo Falconi, Nicola Fazio, Diego Ferone, et al.
Page
of 64